Output Catalog
ASAP is committed to accelerating the pace of discovery and informing a path to a cure for Parkinson’s disease through collaboration, research-enabling resources, and data sharing. We’ve created this catalog to showcase the research outputs and tools developed by ASAP-funded programs.
-
Output Type
-
Program
-
CRN Team Name
-
Theme
LRRK2-mutant microglia and neuromelanin synergize to drive dopaminergic neurodegeneration in an iPSC-based Parkinson’s disease model
PD is a neurodegenerative disorder characterized by the loss of neuromelanin (NM)-containing dopamine neurons. This work highlights NM-activated microglia’s role in PD progression, and provides a model for testing therapeutic targets.
Standardised TruAI automated quantification of intracellular neuromelanin granules in human brain tissue sections
Neuromelanin (NM) granules were analysed in human post-mortem formalin-fixed paraffin embedded (FFPE) midbrain sections.
MRI Datarat brain images used in “Longitudinal neuromelanin changes in prodromal and early Parkinson’s disease in humans and rat model”
This Dataset contains rat brain images used in "Longitudinal neuromelanin changes in prodromal and early Parkinson’s disease in humans and rat model"(DOI: https://doi.org/10.1101/2024.10.22.619619).
Datsets of Article Navigation Journal Article Longitudinal neuromelanin changes in prodromal and early Parkinson’s disease in humans and rat model
Datsets of Article Longitudinal neuromelanin changes in prodromal and early Parkinson’s disease in humans and rat model
Sex-dimorphic effects of neuromelanin buildup in rodent nigral dopamine neurons: implications for sex-biased vulnerability in Parkinson’s disease
Neuromelanin (NM) is pigment accumulating with age in human SNpc dopamine (DA) neurons. This study discloses unrealized NM effects within nigral DA neurons, advancing our comprehension of sex-specific features shaping sex-biased vulnerability to PD.
Datasets of Introducing PIGMO, a novel PIGmented MOuse model of Parkinson’s disease
There is a pressing need for the development of animal models of PD that properly mimic the its cardinal features. Here an AAV engineered to bypass the blood-brain barrier and coding for the human tyrosinase gene is used to generate the PIGMO model.
In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson’s disease
Using a newly developed rodent model, the authors assessed whether the intracellular buildup of neuromelanin that occurs with age can be slowed down in vivo to prevent or attenuate Parkinson’s disease.
Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates
Evidence shows that intracellular aggregation of endogenous alpha-synuclein is triggered by NMel accumulation. Any therapeutic approach to decrease NMel levels may provide appealing choices for the successful implementation of novel PD therapeutics.
Development and characterization of a non-human primate model of disseminated synucleinopathy
The performance and biodistribution of the retrogradely-spreading AAV9-SynA53T vector was evaluated in the NHP brain. Deliveries of viral suspensions in the left putamen gave rise to a disseminated synucleinopathy in a circuit-specific basis.
Systemic inflammation triggers long-lasting neuroinflammation and accelerates neurodegeneration in a rat model of Parkinson’s disease overexpressing human α-synuclein
PD involves genetic and environmental factors, inflammation potentially playing a key role. On rats LPS injection caused inflammation and dopaminergic neuronal loss in Snca+/+ rats, impacting dopamine release. Behavioral changes were not significant.
Intracellular neuromelanin from post-mortem human midbrain and pontine
This data set includes different quantification parameters to identify the features of intracellular neuromelanin.
Source Data for Mendonça et al 2024
Source data and code from dopamine neuron activity encode the length of upcoming contralateral movement sequences by Mendonça et al 2024.
Modelling human neuronal catecholaminergic pigmentation in rodents recapitulates age-related multisystem neurodegenerative deficits
Models for neurodegenerative diseases lack of NM, a pigment found in human brains. A new transgenic mouse model, mimics human distribution and shows age-related neuronal dysfunction and degeneration, offering potential for research in brain aging .
Functional efficacy of the MAO-B inhibitor safinamide in murine substantia nigra pars compacta dopaminergic neurons in vitro: a comparative study with tranylcypromine
Safinamide (SAF) is used for PD by enhancing dopamine signal. SAF prolongs recovery from dopamine-mediated firing inhibition in SNpc DAergic neurons, mildly compared to tranylcypromine, suggesting multiple sites of action for SAF's therapeutics.
